Catalyst Pharmaceuticals, Inc. (CPRX)

NASDAQ: CPRX · IEX Real-Time Price · USD
15.94
-0.16 (-0.99%)
Feb 6, 2023, 3:17 PM EST - Market open
-0.99%
Market Cap 1.66B
Revenue (ttm) 191.76M
Net Income (ttm) 66.92M
Shares Out 104.07M
EPS (ttm) 0.61
PE Ratio 26.20
Forward PE 19.31
Dividend n/a
Ex-Dividend Date n/a
Volume 841,279
Open 16.13
Previous Close 16.10
Day's Range 15.92 - 16.50
52-Week Range 5.61 - 22.11
Beta 1.26
Analysts Buy
Price Target 20.30 (+27.35%)
Earnings Date Mar 15, 2023

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atroph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2006
Employees 76
Stock Exchange NASDAQ
Ticker Symbol CPRX
Full Company Profile

Financial Performance

In 2021, CPRX's revenue was $140.83 million, an increase of 18.27% compared to the previous year's $119.07 million. Earnings were $39.48 million, a decrease of -47.35%.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is $20.3, which is an increase of 27.35% from the latest price.

Price Target
$20.3
(27.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock

Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

3 days ago - Zacks Investment Research

3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence

World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

Other symbols: DYWWE
1 week ago - Zacks Investment Research

3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio

Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.

Other symbols: LWPDD
1 week ago - Zacks Investment Research

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy

1 week ago - GlobeNewsWire

Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

1 week ago - Zacks Investment Research

Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

1 week ago - Zacks Investment Research

3 Reasons Growth Investors Will Love Catalyst (CPRX)

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

2 weeks ago - Zacks Investment Research

Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?

Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

2 weeks ago - Zacks Investment Research

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...

2 weeks ago - GlobeNewsWire

Biotech's Blockbuster Week: 3 Stocks to Watch

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Other symbols: IBBRXDXSAGEXBI
3 weeks ago - Zacks Investment Research

2 Biotechs Making Waves With A Single Product in their Pipeline

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Other symbols: HRMY
3 weeks ago - MarketBeat

Is Most-Watched Stock Catalyst Pharmaceuticals, Inc. (CPRX) Worth Betting on Now?

Catalyst (CPRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

3 weeks ago - Zacks Investment Research

Biotech: 3 Profitable Bios Worth Owning

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.

Other symbols: GILDMRNA
1 month ago - Zacks Investment Research

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

Acquisition Expands The Company's Commercial Portfolio With An Established U.S. Marketed Product

1 month ago - GlobeNewsWire

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Other symbols: UNH
1 month ago - Zacks Investment Research

Catalyst Pharmaceutical (CPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

1 month ago - Zacks Investment Research

Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.

3 months ago - Zacks Investment Research

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates

Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.

3 months ago - Zacks Investment Research

Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase

3 months ago - GlobeNewsWire

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

3 months ago - Zacks Investment Research

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...

3 months ago - GlobeNewsWire